BMS Continues Retreat From Emerging Markets

One of BMI's core views for the pharmaceuticals and healthcare industry is that emerging markets will drive global medicine sales. However, not all drugmakers subscribe to this opinion. For example, US-based Bristol-Myers Squibb (BMS) has sold certain Asian assets to another pharmaceutical company.

To read the full article, please choose one of the following options: